#celularity – Verséa


Verséa Ophthalmics and Celularity Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications

TAMPA, FL. and FLORHAM PARK, N.J., July 27, 2023 — Verséa Ophthalmics, LLC (“Verséa Ophthalmics”), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, and Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that the companies have entered into...